You are here: Industry Insights > MammaPrint

News List

MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care b3cnewswire
June 27, 2019
MammaPrint® Becomes Only Molecular Diagnostic Recommended for Early-Stage Node-Positive Breast Cancer Patients in ASCO-Endorsed Cancer Care Ontario Guidelines.
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology b3cnewswire
June 21, 2019
Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology.
Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized b3cnewswire
March 22, 2018
Agendia, Inc., today announces that its next-generation sequencing -based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Subtyping Kit is now CE marked, enabling the Company to commercialize the device in Europe.